Adenomyosis Treatment Market Research Report -Forecast to 2027

Adenomyosis Treatment Market information, by type (Focal, Adenomyoma, Diffuse and others), by diagnosis (Endometrial biopsy, Ultrasound, Magnetic resonance imaging (MRI), and others), by Treatment (Anti-inflammatory drugs, Hormone medications, Hysterectomy, and others) - Forecast to 2027

ID: MRFR/Pharma/2331-HCR | February 2021 | Region: Global | 76 pages

Market Synopsis of Global Adenomyosis Treatment Market:


Market Scenario:


Adenomyosis disorder also known as Endometriosis interna, Adenomyosis uteri, Endometriosis uterine, or Adenomyometritis. Adenomyosis disorder occurs when endometrial tissue of the uterus endometrial cavity to grow into the uterus muscle that damage the uterine wall the uterine wall grow thicker. It may result into heavy bleeding and pain during the menstrual cysle. Increasing prevalence of adenomyosis is leading the market growth. Rising prevalence of adenomyosis disorder is key factor for the market growth. Increasing knowledge about the disorder and treatment, new drugs and therapies, and advanced medical technology are major driving forces of the global adenomyosis market. Increasing funding for R&D to develop more advanced product for the market is another key driver for the market.

The Adenomyosis Treatment market is growing at the CAGR of ~4.1% during the forecast period and expected to reach US$ 291.5 million by 2023.

Study objectives of Global Adenomyosis Treatment Market:


  • To provide detailed analysis of the Global market structure with historical and forecast revenue for the next 7 years of the various segments and sub-segments of the adenomyosis treatment market

  • To provide insights about the key drivers, restraints, opportunities and challenges that affecting the growth of the adenomyosis treatment market

  • To provide analysis of the market with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.

  • To provide detail analysis of the market that segmented on the basis of type, by diagnosis, by treatment, and its sub-segments.

  • To provide detail analysis of global market mainly based on value chain adenomyosis analysis, Porter’s five forces, Price analysis, and Supply Chain analysis etc.

  • To provide detail country level analysis of the market with respect to the current market size and future prospective

  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Global Market

  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the Adenomyosis Treatment market


FIGURE 1                   ADENOMYOSIS TREATMENT GLOBAL MARKET SHARE, BY DIAGNOSIS (%)

 


Key Players for Global Adenomyosis Treatment Market:                          


Some of the key players in this market are: Bayer AG (Germany), Ferring B.V. (Switzerland), Johnson & Johnson Consumer Inc. (US), Novartis (Switzerland), Merck KGaA (Germany), Pfizer Inc. (US), Speciality European Pharma (UK)


Segments:      


Global adenomyosis treatment Market has been segmented on the basis of type which Focal, Adenomyoma, Diffuse, and others. On the basis of diagnosis, it is segmented into endometrial biopsy, ultrasound (transabdominal, transvaginal/endovaginal), and magnetic resonance imaging (MRI). On the basis of treatment, the market is segmented into anti-inflammatory drugs (ibuprofen, Motrin IB, Advil, and others), hormone medications (Gonadotropin-releasing hormone (GnRH) agonists, Aromatase inhibitors), Hysterectomy (supracervial or subtotal hysterectomy, Total hysterectomy, Radical hysterectomy), and others.


Research Methodology:

 Sources: Directorate of Industries, Annual report, White paper, Company Presentation


 


Regional Analysis of Global Adenomyosis Treatment Market:                        


Considering the global scenario of the market, due to continuous innovation and rapid adoption of new drugs and therapies, North America is largest market for Adenomyosis Treatment. US is holding largest market share in North America region. European market is second largest, and especially the growth rate is higher in west European countries. On the other hand, due increasing knowledge of disease and treatments, developing healthcare infrastructure, and increasing healthcare expenditure, the Asia-Pacific (APAC) is fastest growing market for adenomyosis and expected to grow significantly during the forecast period. Middle East and Africa (ME&A) is likely to have a limited growth in the market due to less awareness of devices and treatment. 


Intended Audience



  • Adenomyosis Treatment drugs manufacturers

  • Adenomyosis Treatment drugs providers

  • Hospitals and clinics

  • Medical Research laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors



Report Scope:
Report Attribute/Metric Details
  Market Size   US$ 291.5 Million
  CAGR   2017-2023: ~4.1%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   By Type, Diagnosis and Treatment
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Bayer AG (Germany), Ferring B.V. (Switzerland), Johnson & Johnson Consumer Inc. (US), Novartis (Switzerland), Merck KGaA (Germany), Pfizer Inc. (US), Speciality European Pharma (UK)
  Key Market Opportunities   funding for R&D to develop more advanced product
  Key Market Drivers   Knowledge on novel drugs and therapies, awareness of the disorder, and advanced technology


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :


adenomyosis treatment market size can touch USD 291.5 million by 2023.

adenomyosis treatment market can progress at 4.1% CAGR from 2016 to 2023.

Knowledge on novel drugs and therapies, awareness of the disorder, and advanced technology are major drivers of the global adenomyosis treatment market.

North America holds the largest share in the global adenomyosis treatment market.

Ferring B.V., Merck KGaA, Novartis, Johnson & Johnson Consumer Inc., Bayer AG, Pfizer Inc., and Speciality European Pharma are major players of the global adenomyosis treatment market.

Table of Content
1. Report Prologue

2. Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

2.3 Market Structure

2.4. Market Segmentation

3. Research Methodology

3.1 Research Process

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

3.5 Forecast Model

4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Mega Trends

4.5 Macroeconomic Indicators

5. Market Factor analysis

5.1 Value Chain Analysis

5.2 Porters Five Forces

5.3 Demand & Supply: Gap Analysis

5.4 Pricing Analysis

5.5 Investment Opportunity Analysis

5.6 Merger and Acquisition Landscape

5.7 Upcoming trends

5.7.1 Market trends

5.7.2 Technological trends

5.7.3 Insurance & Regulations

5.7.4 Others

6. Global Adenomyosis Treatment Market by Type

6.1 Focal

6.2 Adenomyoma

6.3 Diffuse

6.4 Others

7. Global Adenomyosis Treatment Market by Diagnosis

7.1 Endometrial biopsy

7.2 Ultrasound

7.2.1 Transabdominal

7.2.2 Transvaginal/endovaginal

7.3 Magnetic resonance imaging (MRI)

7.4 Others

8. Global Adenomyosis Treatment Market by Treatment

8.1 Anti-inflammatory drugs

8.1.1 Ibuprofen

8.1.2 Motrin IB

8.1.3 Advil

8.1.4 Others

8.2 Hormone medications

8.2.1 Gonadotropin-releasing hormone (GnRH) agonists

8.2.2 Aromatase inhibitors

8.2.3 Others

8.3 Hysterectomy

8.3.1 Supracervial or subtotal hysterectomy

8.3.2 Total hysterectomy

8.3.3 Radical hysterectomy

8.4 Others

9. Global Adenomyosis Treatment Market by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 The US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.3 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia

9.4.1 China

9.4.2 India

9.4.3 Japan

9.4.4 South Korea

9.4.5 Rest of Asia

9.5 Pacific

9.6 Middle East and Africa

9.6.1 UAE

9.6.2 Saudi Arabia

9.6.3 Egypt

9.6.4 Rest of Middle East and Africa

10. Competitive landscape

11. Company profile

12 Conclusion

12.1 Key findings

10.1.1 From CEO’s viewpoint

10.1.2 Unmet needs of the market

12.2 Key companies to watch

12.3 Prediction of Adenomyosis Treatment Market

13 Appendix